Novel concepts in airway inflammation and remodelling in asthma

The hallmark pathological features of asthma include airway eosinophilic inflammation and structural changes (remodelling) which are associated with an irreversible loss in lung function that tracks from childhood to adulthood. In parallel with changes in function, pathological abnormalities occur early, during the pre-school years, are established by school age and subsequently remain (even though symptoms may remit for periods during adulthood). Given the equal importance of inflammation and remodelling in asthma pathogenesis, there is a significant disparity in studies undertaken to investigate the contribution of each. The majority focus on the role of inflammation, and although novel therapeutics such as those targeted against T-helper cell type 2 (Th2) mediators have arisen, it is apparent that targeting inflammation alone has not allowed disease modification. Therefore, unless airway remodelling is addressed for future therapeutic strategies, it is unlikely that we will progress towards a cure for asthma. Having acknowledged these limitations, the focus of this review is to highlight the gaps in our current knowledge about the mechanisms underlying airway remodelling, the relationships between remodelling, inflammation and function, remodelling and clinical phenotypes, and the importance of utilising innovative and realistic pre-clinical models to uncover effective, disease-modifying therapeutic strategies. We discuss mechanisms of airway inflammation and remodelling in asthma to uncover effective therapeutic strategies http://ow.ly/SsXiO

[1]  Borislav D. Dimitrov,et al.  Innate and adaptive T cells in asthmatic patients: Relationship to severity and disease mechanisms , 2015, The Journal of allergy and clinical immunology.

[2]  P. Gosset,et al.  Airway Remodeling in Preschool Children with Severe Recurrent Wheeze. , 2015, American journal of respiratory and critical care medicine.

[3]  S. Johnston,et al.  Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons , 2015, The Journal of allergy and clinical immunology.

[4]  Richard J Martin,et al.  Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. , 2015, The Journal of allergy and clinical immunology.

[5]  S. Saglani,et al.  Epithelial cytokines and pulmonary allergic inflammation. , 2015, Current opinion in immunology.

[6]  Dong Hyun Kim,et al.  Bioengineering the Lung : Molecules , Materials , Matrix , Morphology , and Mechanics Matrix stiffness-modulated proliferation and secretory function of the airway smooth muscle cells , 2015 .

[7]  C. Bachert,et al.  Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. , 2015, The New England journal of medicine.

[8]  K. Chung,et al.  Increased phenotypic differentiation and reduced corticosteroid sensitivity of fibrocytes in severe asthma. , 2015, The Journal of allergy and clinical immunology.

[9]  E. Gelfand,et al.  The other side of asthma: Steroid-refractory disease in the absence of TH2-mediated inflammation. , 2015, The Journal of allergy and clinical immunology.

[10]  F. Laurent,et al.  Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. , 2015, American journal of respiratory and critical care medicine.

[11]  U. Demkow,et al.  Neutrophils in asthma—A review , 2015, Respiratory Physiology & Neurobiology.

[12]  C. Brightling,et al.  IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk , 2015, Allergy.

[13]  M. Bonsignore,et al.  Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience , 2015, European Respiratory Review.

[14]  R. Bals,et al.  The innate immune function of airway epithelial cells in inflammatory lung disease , 2015, European Respiratory Journal.

[15]  S. Wenzel,et al.  Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. , 2015, The Journal of allergy and clinical immunology.

[16]  S. Wenzel,et al.  Emerging molecular phenotypes of asthma. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[17]  A. Lowe,et al.  Age-of-asthma onset as a determinant of different asthma phenotypes in adults: a systematic review and meta-analysis of the literature , 2015, Expert review of respiratory medicine.

[18]  A. James,et al.  Distribution of airway smooth muscle remodelling in asthma: Relation to airway inflammation , 2015, Respirology.

[19]  aí®®ÿ∫ —π¬—߉¡à¡’§”®”°—¥§«“¡¢Õß Remission of asthma , 2015 .

[20]  A. Magnan,et al.  IL-17 in severe asthma. Where do we stand? , 2014, American journal of respiratory and critical care medicine.

[21]  G. Canonica,et al.  Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. , 2014, Immunology letters.

[22]  E. Nizankowska-Mogilnicka,et al.  Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma , 2014, Allergy.

[23]  S. Johnston,et al.  The role of macrolides in asthma: current evidence and future directions. , 2014, The Lancet. Respiratory medicine.

[24]  Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma , 2014, European Respiratory Journal.

[25]  J. Monteseirín,et al.  Neutrophils from allergic asthmatic patients produce and release metalloproteinase-9 upon direct exposure to allergens. , 2014, Allergy.

[26]  P. Sly,et al.  Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy , 2014, Thorax.

[27]  M. Nawijn,et al.  Airway epithelial barrier function regulates the pathogenesis of allergic asthma , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[28]  C. Robertson,et al.  The association between childhood asthma and adult chronic obstructive pulmonary disease , 2014, Thorax.

[29]  Salman Siddiqui,et al.  Quantitative computed tomography–derived clusters: Redefining airway remodeling in asthmatic patients☆ , 2014, The Journal of allergy and clinical immunology.

[30]  I. Pavord,et al.  Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. , 2014, The Journal of allergy and clinical immunology.

[31]  W. Calhoun,et al.  Heterogeneity of asthma in society. , 2014, Advances in experimental medicine and biology.

[32]  Thomas Blicher,et al.  A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations , 2013, Nature Genetics.

[33]  J. Fahy Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[34]  C. Hawrylowicz,et al.  Defective IL-10 expression and in vitro steroid-induced IL-17A in paediatric severe therapy-resistant asthma , 2013, Thorax.

[35]  P. Gibson,et al.  Galectin-3: its role in asthma and potential as an anti-inflammatory target , 2013, Respiratory Research.

[36]  J. Ward,et al.  The relationship between eosinophilia and airway remodelling in mild asthma , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[38]  P. Devillier,et al.  The expression and relaxant effect of bitter taste receptors in human bronchi , 2013, Respiratory Research.

[39]  P. Ryan,et al.  Diesel exhaust particle induction of IL-17A contributes to severe asthma. , 2013, The Journal of allergy and clinical immunology.

[40]  L. Gregory,et al.  Endothelin-1 directs airway remodeling and hyper-reactivity in a murine asthma model , 2013, Allergy.

[41]  S. Cheney Azithromycin for Prevention of Exacerbations in Severe Asthma: A Multicentre Randomized Double Blind Placebo-controlled Trial , 2013 .

[42]  A. Bush,et al.  IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. , 2013, The Journal of allergy and clinical immunology.

[43]  A. Zwinderman,et al.  Severe adult-onset asthma: A distinct phenotype. , 2013, The Journal of allergy and clinical immunology.

[44]  A. Zwinderman,et al.  Three phenotypes of adult‐onset asthma , 2013, Allergy.

[45]  W. Banya,et al.  Increased airway smooth muscle in preschool wheezers who have asthma at school age. , 2013, The Journal of allergy and clinical immunology.

[46]  M. Mäkelä,et al.  Remodeling, inflammation and airway responsiveness in early childhood asthma , 2013, Current opinion in allergy and clinical immunology.

[47]  S. Gupta,et al.  Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma , 2013, Respiratory Research.

[48]  Johny Verschakelen,et al.  Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial , 2013, Thorax.

[49]  E. R. Sutherland,et al.  A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. , 2012, American journal of respiratory and critical care medicine.

[50]  Ville Pulkkinen,et al.  Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics , 2012, European Respiratory Journal.

[51]  D. Knight,et al.  Human airway epithelial cell innate immunity: relevance to asthma. , 2012, Current opinion in immunology.

[52]  Stephen T. Holgate,et al.  Barrier responses of human bronchial epithelial cells to grass pollen exposure , 2012, European Respiratory Journal.

[53]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[54]  S. Wenzel Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[55]  Dave Singh,et al.  A Comparison of the Clinical and Induced Sputum Characteristics of Early- and Late-Onset Asthma , 2012, Lung.

[56]  A. Bush,et al.  Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. , 2012, The Journal of allergy and clinical immunology.

[57]  N. Wilson,et al.  Sputum inflammatory phenotypes are not stable in children with asthma , 2012, Thorax.

[58]  J. Stockman,et al.  A Large-Scale, Consortium-Based Genomewide Association Study of Asthma , 2012 .

[59]  L. Nicod,et al.  [Late-onset asthma]. , 2011, Revue medicale suisse.

[60]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[61]  C. Brightling,et al.  Evidence for phenotype-driven treatment in asthmatic patients , 2011, Current opinion in allergy and clinical immunology.

[62]  Stephen T Holgate,et al.  Animal models of asthma: value, limitations and opportunities for alternative approaches. , 2011, Drug discovery today.

[63]  B. Levy,et al.  Faculty Opinions recommendation of Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. , 2011 .

[64]  D. Postma,et al.  Persisting remodeling and less airway wall eosinophil activation in complete remission of asthma. , 2011, American journal of respiratory and critical care medicine.

[65]  M. Jordana,et al.  Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease. , 2011, American journal of respiratory and critical care medicine.

[66]  P. Gibson,et al.  Different inflammatory phenotypes in adults and children with acute asthma , 2011, European Respiratory Journal.

[67]  Florence Demenais,et al.  A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.

[68]  L. Gregory,et al.  Overexpression of Smad2 drives house dust mite-mediated airway remodeling and airway hyperresponsiveness via activin and IL-25. , 2010, American journal of respiratory and critical care medicine.

[69]  C. Lemière,et al.  Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. , 2010, The Journal of allergy and clinical immunology.

[70]  S. Saglani,et al.  Asthma and allergy: The emerging epithelium , 2010, Nature Medicine.

[71]  A. Kay,et al.  Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma. , 2009, The Journal of allergy and clinical immunology.

[72]  A. Bush,et al.  Pathophysiological features of asthma develop in parallel in house dust mite-exposed neonatal mice. , 2009, American journal of respiratory cell and molecular biology.

[73]  T. Mahr Early Detection of Airway Wall Remodeling and Eosinophilic Inflammation in Preschool Wheezers , 2008, Pediatrics.

[74]  M. Ochs,et al.  Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. , 2008, American journal of respiratory and critical care medicine.

[75]  S. Holgate The airway epithelium is central to the pathogenesis of asthma. , 2008, Allergology international : official journal of the Japanese Society of Allergology.

[76]  J. Malo,et al.  Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[77]  P. Maestrelli,et al.  Recovery from adult‐onset asthma and airway remodelling , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[78]  Andrew Bush,et al.  Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. , 2007, American journal of respiratory and critical care medicine.

[79]  L. Fabbri,et al.  Epithelial damage and angiogenesis in the airways of children with asthma. , 2006, American journal of respiratory and critical care medicine.

[80]  H. Bisgaard,et al.  Intermittent inhaled corticosteroids in infants with episodic wheezing. , 2006, The New England journal of medicine.

[81]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[82]  N. Thomson,et al.  in smokers with asthma , 2006 .

[83]  T. Haahtela,et al.  Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. , 2005, American journal of respiratory and critical care medicine.

[84]  P. Woodruff,et al.  Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. , 2004, American journal of respiratory and critical care medicine.

[85]  S. Wenzel,et al.  Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. , 2004, The Journal of allergy and clinical immunology.

[86]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[87]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[88]  I. Pavord,et al.  Mast-cell infiltration of airway smooth muscle in asthma. , 2002, The New England journal of medicine.

[89]  P. Roe,et al.  Pulmonary disease , 1991 .

[90]  E. Daniel,et al.  Airway Smooth Muscle Cells , 1998 .

[91]  J. Shelhamer,et al.  Airway Inflammation , 1995, Annals of Internal Medicine.

[92]  D. Leung Steroid-resistant asthma. , 1995, The Western journal of medicine.

[93]  Robert S. Pinals,et al.  A double‐blind, placebo‐controlled trial , 1986 .